Does FFAR4 agonism have therapeutic potential in cardiometabolic disease?

Abigail C Lay*

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

1 Citation (Scopus)
116 Downloads (Pure)
Original languageEnglish
Article numberbqab145
JournalEndocrinology
Volume162
Issue number10
Early online date20 Jul 2021
DOIs
Publication statusPublished - 1 Oct 2021

Keywords

  • FFAR4
  • GPR120
  • diabetes
  • obesity
  • metabolic syndrome
  • cardiometabolic disease
  • vascular disease
  • atherosclerosis
  • CVD

Access to Document

  • Full-text PDF (author’s accepted manuscript)

    This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford University Press at https://doi.org/10.1210/endocr/bqab145 . Please refer to any applicable terms of use of the publisher. This journal has made an ‘accepted manuscript’ proof version openly available on the journal website. When the online version is updated from the AAM to the VOR, please download the VOR and add it to this record, then restrict the AAM

    Accepted author manuscript, 587 KBLicence: CC BY-NC-ND
  • Full-text PDF (final published version)

    This is the final published version of the article (version of record). It first appeared online via Oxford Academic at https://doi.org/10.1210/endocr/bqab145 . Please refer to any applicable terms of use of the publisher.

    Final published version, 118 KBLicence: CC BY-NC-ND

Handle.net

    Embargoed Document

  • PLACEHOLDER

    45 KB

    Embargo ends: 1/01/99

    Request copy

Cite this